Drug Sponsors

Certara launches Global Quantitative Systems Pharmacology Consortium

Wednesday, January 25, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s Simcyp Consortium, and believed to be the first of its kind, the QSP Immunogenicity Consortium brings together biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator that will predict immunogenicity of biologics and its impact on their pharmacokinetics, efficacy and safety in diverse patient populations.

[Read More]

Chan Zuckerberg Initiative to acquire AI startup Meta

Tuesday, January 24, 2017

iGan Partners is thrilled to announce the pending acquisition of its portfolio company, Meta, by the Chan Zuckerberg Initiative. Launched in 2015 by Mark Zuckerberg and Dr. Priscilla Chan, the Chan Zuckerberg Initiative is dedicated to advancing human potential and promoting equal opportunity, with a current focus on scientific research, education, and building strong communities. The goal of their science initiative is to cure, prevent, or manage all diseases by the end of this century.

[Read More]

FDA Oncology Center of Excellence launches

Monday, January 23, 2017

The FDA is establishing the Oncology Center of Excellence (OCE) and appointing Dr. Richard Pazdur as its director. This will make oncology the first disease area to have a coordinated clinical review of drugs, biologics and devices across the agency’s three medical product centers.

[Read More]

PharmAthene, Altimmune merge

Friday, January 20, 2017

PharmAthene and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’s previously announced special one-time cash dividend of $2.91 per share of common stock.

[Read More]

MRC Technology Centre relocates to expand diagnostics research capability

Tuesday, January 17, 2017

MRC Technology, an independent medical research charity, has announced the relocation of its Centre for Diagnostics Development (CDD) to Nine, Edinburgh BioQuarter, in the U.K. The move forms part of the charity’s investment of over £7 million over the next five years to further its work accelerating diagnostic research into the clinic. CDD will potentially double its headcount over the same period.

[Read More]

Nivalis Therapeutics restructures

Monday, January 16, 2017

Nivalis Therapeutics, a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), has announced that its board of directors has approved a restructuring plan as part of the company’s initiative to explore strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.

[Read More]

Report: Biopharmaceutical M&A expected to soar in 2017

Monday, January 16, 2017

The biopharmaceutical industry’s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M&A) environment in 2017. This is according to the EY M&A Outlook and Firepower Report 2017. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election U.S., expectations are that the industry may roar past the $200 billion in global M&A deal volume seen in the last three years.

[Read More]